Market closedNon-fractionalADR
Nanobiotix/NBTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nanobiotix
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Ticker
NBTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Paris, France
Employees
102
Website
www.nanobiotix.com
Nanobiotix Metrics
BasicAdvanced
$331M
Market cap
-
P/E ratio
-$1.19
EPS
0.31
Beta
-
Dividend rate
Price and volume
Market cap
$331M
Beta
0.31
52-week high
$11.00
52-week low
$4.89
Average daily volume
0.77
Financial strength
Current ratio
1.751
Interest coverage (TTM)
-1.98%
Management effectiveness
Return on assets (TTM)
-51.67%
Return on investment (TTM)
-120.56%
Valuation
Price to revenue (TTM)
10.168
Growth
Earnings per share change (TTM)
32.74%
3-year revenue growth (CAGR)
743.97%
What the Analysts think about Nanobiotix
Analyst Ratings
Majority rating from 5 analysts.
Nanobiotix Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€30M
∞%
Net income
-€12M
-58.57%
Profit margin
-38.66%
-∞%
Nanobiotix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q4 23
Actual
-€0.80
-
Expected
-
-€0.82
Surprise
-
-
Nanobiotix News
AllArticlesVideos
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
GlobeNewsWire·1 month ago
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
GlobeNewsWire·2 months ago
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $331M as of July 27, 2024.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of July 27, 2024.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Nanobiotix stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.